Sinopep-Allsino Biopharmaceutical Co., Ltd. is a leading biopharmaceutical company based in China, focusing on the research, development, and production of peptide drugs, small molecule drugs, and oligonucleotide drugs. Established in 2009, the company operates multiple R&D and manufacturing sites, including facilities in Hangzhou and Lianyungang. Sinopep-Allsino is known for its advanced technology and high-quality CRDMO (Contract Research, Development, and Manufacturing Organization) services, providing end-to-end solutions from laboratory research to commercial production. The company has passed multiple FDA inspections and holds significant expertise in developing APIs for highly demanded peptide products such as Semaglutide, Tirzepatide, and Liraglutide.